OTCMKTS:AIMD Ainos (AIMD) Stock Price, News & Analysis → Collect 10%+ Dividends from AI's Explosive Growth? (From The Oxford Club) (Ad) Free AIMD Stock Alerts $0.82 -0.03 (-3.53%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$0.82▼$0.8550-Day Range$0.80▼$1.2652-Week Range$0.77▼$6.10Volume10,894 shsAverage Volume1.10 million shsMarket Capitalization$5.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsStock AnalysisChartEarningsFinancialsHeadlinesSEC Filings Get Ainos alerts: Email Address Ad The Freeport SocietyBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. About Ainos Stock (OTCMKTS:AIMD)Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Read More AIMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AIMD Stock News HeadlinesMay 15, 2024 | finanznachrichten.deAinos, Inc.: Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential MarketMarch 11, 2024 | msn.comSOS, MFG and LYT among pre-market losersMarch 10, 2024 | finance.yahoo.comAinos Full Year 2023 Earnings: US$3.36 loss per share (vs US$5.14 loss in FY 2022)March 8, 2024 | finanznachrichten.deAinos, Inc.: Ainos Reports Full Year 2023 Financial ResultsMarch 8, 2024 | markets.businessinsider.comNasdaq Gains Over 50 Points; US Economy Adds 275,000 Jobs In FebruaryMarch 4, 2024 | edition.cnn.comAinos IncFebruary 23, 2024 | benzinga.comAinos Stock (NASDAQ:AIMD), Short Interest ReportFebruary 8, 2024 | finance.yahoo.comSmall-Cap Growth Virtual Investor Conference Presentations Now Available for Online ViewingFebruary 1, 2024 | finance.yahoo.comAinos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7thJanuary 5, 2024 | msn.comUS Stocks Higher; Payrolls Increase By 216,000 In DecemberJanuary 5, 2024 | investorplace.comWhy Is Ainos (AIMD) Stock Up 157% Today?January 2, 2024 | finanznachrichten.deAinos, Inc.: Ainos Regains Compliance with Nasdaq Minimum Bid Price RequirementJanuary 2, 2024 | finance.yahoo.comAinos Regains Compliance with Nasdaq Minimum Bid Price RequirementDecember 26, 2023 | finance.yahoo.comAinos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of SmellDecember 12, 2023 | msn.comAinos implements a reverse stock splitDecember 12, 2023 | finance.yahoo.comAinos, Inc. Announces Stock ConsolidationNovember 28, 2023 | finance.yahoo.comAinos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss PharmaceuticalNovember 10, 2023 | msn.comAinos GAAP EPS of -$0.15November 9, 2023 | finance.yahoo.comAinos Reports Third Quarter 2023 Financial ResultsNovember 8, 2023 | morningstar.comAinos Inc AIMDNovember 6, 2023 | finance.yahoo.comAinos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONASeptember 25, 2023 | finance.yahoo.comAinos Announces Placement of Initial $3 Million Tranche of $10 Million Private PlacementSeptember 19, 2023 | finance.yahoo.comWith Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV PatientsSeptember 18, 2023 | finanznachrichten.deAinos, Inc.: Ainos' VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive PatientsSeptember 18, 2023 | finance.yahoo.comAinos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive PatientsSee More Headlines Receive AIMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ainos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolOTCMKTS:AIMD CUSIPN/A CIK1014763 Webwww.amarbio.com Phone(858) 869-2986Fax806-376-9301Employees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,010,000.00 Net Margins-515.80% Pretax Margin-515.76% Return on Equity-44.32% Return on Assets-40.35% Debt Debt-to-Equity Ratio0.08 Current Ratio1.92 Quick Ratio1.45 Sales & Book Value Annual Sales$93,677.00 Price / Sales56.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book0.55Miscellaneous Outstanding Shares6,503,000Free Float13,322,000Market Cap$5.33 million OptionableNot Optionable Beta1.39 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Chun-Hsien Tsai (Age 54)Chairman of Board, President & CEO Comp: $112.12kMr. Lawrence Kennedy Lin (Age 55)Executive Vice President of Operations Comp: $144kMr. Hsin-Liang Lee (Age 53)Chief Financial Officer Mr. Chih-Heng Lu (Age 44)Director of Corporate Developoment Key CompetitorsBiotricityOTCMKTS:BTCYBone BiologicsOTC:BBLGAinosNASDAQ:AIMDWBICO Group AB (publ)OTCMKTS:CLLKFBone BiologicsNASDAQ:BBLGWView All Competitors AIMD Stock Analysis - Frequently Asked Questions How have AIMD shares performed in 2024? Ainos' stock was trading at $2.05 at the beginning of the year. Since then, AIMD stock has decreased by 60.0% and is now trading at $0.8202. View the best growth stocks for 2024 here. How were Ainos' earnings last quarter? Ainos, Inc. (OTCMKTS:AIMD) issued its earnings results on Monday, May, 13th. The company reported ($0.57) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter. Ainos had a negative net margin of 515.80% and a negative trailing twelve-month return on equity of 44.32%. When did Ainos' stock split? Ainos shares reverse split before market open on Tuesday, August 9th 2022. The 1-15 reverse split was announced on Tuesday, August 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Ainos? Shares of AIMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:AIMD) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.